Breast cancer cell survival signal is affected by bergapten combined with an ultraviolet irradiation

FEBS Letters

Volumn 584, Issue 11, 2010, Pages 2321-2326

  Panno, Maria Luisa ^a   Giordano, Francesca ^a   Mastroianni, Fabrizia ^a   Palma, M Grazia ^a   Bartella, Viviana ^a   Carpino, Amalia ^a   Aquila, Saveria ^a   Andò, Sebastiano ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

Author keywords

Apoptosis; Bergapten; Cell survival; P21 PCNA; P53

Indexed keywords

BERGAPTEN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLINE; DNA; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; SOMATOMEDIN C;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STIMULATION; CELL STRAIN MCF 7; CELL SURVIVAL; CONTROLLED STUDY; DNA REPLICATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; PHOTOACTIVATION; PRIORITY JOURNAL; PROTEIN CONTENT; PUVA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; INSULIN-LIKE GROWTH FACTOR I; METHOXSALEN; PHOTOSENSITIZING AGENTS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952958492     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2010.04.001     Document Type: Article

References (19)

1. Parrish J.A., Fitzpatrick T.B., Tanenbaum L., Pathak M.A. Photochemotherapy of psoriasis with oral methoxalen and longwave ultraviolet light. N. Engl. J. Med. 1974, 291:1207-1211.
2. Honig B., Morison W.L., Karp D. Photochemotherapy beyond psoriasis. J. Am. Acad. Dermatol. 1994, 31:775-790.
3. Luftl M., Degitz K., Plewig G., Rocken R. Psoralen bath plus UV-A therapy-possibilities and limitations. Arch. Dermatol. 1997, 133:1597-1603.
4. Balogh A., Merkel U., Looks A., Vollandt R., Wollina U. Drug monitoring of orally administered 8-methoxypsoralen in patients treated with extracorporeal photopheresis. Skin Pharmacol. Appl. Skin Phyisiol. 1998, 11:258-265.
5. Plumas J., Drillat P., Jacob M.C., Richard M.J., Favrot M.C. Extracorporeal photochemotherapy for treatment of clonal T cell proliferations. Bull. Cancer 2003, 90:763-770.
6. Baden H.P., Parrington J.M., Delhanty J.D., Pathak M.A. DNA synthesis in normal and xeroderma pigmentosum fibroblasts following treatment with 8-methoxypsoralen and long wave ultraviolet light. Biochim. Biophys. Acta. 1972, 262:247-255.
7. Tokura Y., Edelson R.L., Gasparro F.P. Formation and removal of 8-MOP-DNA photoadducts in keratinocytes: effects of calcium concentration and retinoids. J. Invest. Dermatol. 1991, 96:942-949.
8. Kao C.H., Yu H.S. Comparison of the effect of 8-methoxypsoralen (8-MOP) plus UVA (PUVA) on human melanocytes in vitiligo vulgaris and in vitro. J. Invest. Dermatol. 1992, 98:734-740.
9. Scherer R., Kern B., Braun-Falco O. The human peripheral lymphocyte - a model system for studying the combined effect of psoralen plus black light. Klin. Wochenschr. 1997, 55:137-140.
10. Morison W.L. Photoimmunologic effects of psoralens and UVA. Proc. Int. Psoralens SIR Pergamon Press 1981, 3:15-325.
11. Marks D.I., Fox R.M. Mechanism of photochemotherapy - induced apoptotic cell death in lymphoid cells. Biochem. Cell. Biol. 1991, 69:754-760.
12. Yoo E.K., Rook A.H., Elenitsas R., Gasparro F.P., Vowels B.R. Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action. J. Invest. Dermatol. 1996, 107:235-242.
13. Panno M.L., Giordano F., Palma M.G., Bartella V., Rago V., Maggiolini M., Sisci D., Lanzino M., De Amicis F., Andò S. Evidence that bergapten, independently of its photoactivation, enhances p53 gene expression and induces apoptosis in human breast cancer cells. Curr. Cancer Drug Targets 2009, 4:469-481.
14. Panno M.L., Giordano F., Mastroianni F., Morelli C., Brunelli E., Palma M.G., Pellegrino M., Aquila S., Miglietta A., Mauro L., Bonofiglio D., Andò S. Evidence that low doses of Taxol enhance the functional transactivatory properties of p53 on p21 waf promoter in MCF-7 breast cancer cells. FEBS Lett. 2006, 580:2371-2380.
15. Surmacz E., Guvakova M.A., Nolan M.K., Nicosia R.F., Sciacca L. Type I insulin-like growth factor receptor function in breast cancer. Breast Cancer Res. Treat. 1998, 3:255-267.
16. Arteaga C.L. Interference of the IGF system as a strategy to inhibit breast cancer growth. Breast Cancer Res. Treat. 1992, 22:101-106.
17. Lee A.V., Yee D. Insulin-like growth factors and breast cancer. Biomed. Pharmacother. 1995, 49:415-421.
18. Miyashita T., Harigai M., Hanada M., Reed J.C. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994, 54:3131-3135.
19. Mayo L.D., Donner D.B. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem. Sci. 2002, 27:462-467.